Pulmonary carcinosarcoma initially presenting as invasive aspergillosis: a case report of previously unreported combination
© Olobatoke et al; licensee BioMed Central Ltd. 2010
Received: 6 November 2009
Accepted: 29 January 2010
Published: 29 January 2010
Carcinosarcoma of the lung is a malignant tumor composed of a mixture of carcinoma and sarcoma elements. The carcinomatous component is most commonly squamous followed by adenocarcinoma. The sarcomatous component commonly comprises the bulk of the tumor and shows poorly differentiated spindle cell features. Foci of differentiated sarcomatous elements such as chondrosarcoma and osteosarcoma may be seen. Aspergillus pneumonia is the most common form of invasive aspergillosis and occurs mainly in patients with malignancy, immunocompromizing or debilitating diseases. Patients with Aspergillus pneumonia present with fever, cough, chest pain and occasionally hemoptysis. Tissue examination is the most reliable method for diagnosis, and mortality rate is high.
We describe a case of primary carcinosarcoma of the lung concurrently occurring with invasive pulmonary aspergillosis in a 66-year old patient.
Primary carcinosarcoma of the lung is exceedingly rare [1–8]. In the new World Health Organization (WHO) classification of lung tumors, it is described as malignancy composed of a mixture of carcinoma and sarcoma elements. The sarcomatous is usually spindle cell but may contain cartilage, bone or skeletal muscle components. However, controversy exists in the classification of this tumor and some authors may include sarcomatoid carcinoma in this category.
Invasive pulmonary aspergillosis is a spectrum of reactions that depend on a combination of patient immunologic status, underlying lung condition and the nature of exposure to aspergillus fungus. It most often presents as aspergillus pneumonia and almost always involves immunoecompromized or debilitated patients with underlying malignancy . Acute leukemia patients are very susceptible particularly during times of neutropenia. Patients with cirrhosis, chronic obstructive pulmonary disease (COPD), autoimmune deficiency syndrome (AIDS) and prolonged steroid treatment are at increased risk. Here we report a case of primary pulmonary carcinosarcoma with synchronous aspergillous pneumonia in a patient with previous prostate cancer. On review of the literature, this combination has not been reported before.
A 66 years old African American man presented to the hospital with 1 week history of progressive shortness of breath and bilateral calf pain. He complained of occasional productive cough but denied any chest pain, hemoptysis, night sweats, palpitation, or dyspnea. He had a history of peripheral vascular disease and prostate cancer Gleason's score 6(3+3) about 8 years ago for which he had prostatectomy and subsequent penile implant for erectile dysfunction. He had an extensive smoking history but no alcohol or street drug abuse. Furthermore, he had a prior 8-year history of incarceration and a family history of lung cancer.
Pulmonary function test showed an obstructive pattern (FEV1/FVC ratio 58% of reference). He subsequently had a thoracotomy with a left upper lobectomy revealing biphasic malignant tumor (carcinosarcoma).
Additionally, intraoperatively obtained pleural fluid showed many malignant cells arranged in sheets and single cell pattern. The tumor cells were round to spindle and highly pleomorphic. Immunostains for CK 5/6, CK 7, CK 20, TTF-1, CD 15 and CD 30 were all negative in the tumor cells.
Unfortunately, our patient had a complicated postoperative course in the intensive care unit. He developed pneumonia with Acinetobacter and was difficult to wean him from the ventilator. He finally succumbed to cardiac arrest.
Pulmonary carcinosarcoma is a malignant tumor with a mixture of carcinoma and sarcoma [1, 2]. In the WHO classification of lung tumors, it is included in a group of poorly differentiated non-small cell lung carcinomas that contain a component of sarcomatoid differentiation, so called sarcomatoid carcinoma. The average age of diagnosis is 60 years with men to women ratio of 4:1 and more than 90% of these patients have a history of heavy smoking . Pulmonary carcinosarcoma accounts for < 1% of all primary pulmonary neoplasms .
The carcinomatous component is more often squamous cell carcinoma, followed by adenocarcinoma and large cell carcinoma; whereas the most common mesenchymal component is poorly differentiated spindle cell sarcoma. Nevertheless, foci of rhabdomyosarcoma, osteosarcoma, and chondrosarcoma are often found .
In a retrospective analysis of 2,400 lung cancer patients between 1975 and 1995 conducted by Huwer H et al, only seven patients (0.3%) had pulmonary carcinosarcoma . Diaconita reported eight cases among 3000 patients with malignant pulmonary tumors .
Immunohistochemical (IHC) staining enhances the distinction of carcinomatous from sarcomatous components within the tumor. When heterologous sarcoma elements such as cartilage or skeletal muscle are present, it is easier to confirm the biphasic nature of the tumor, although immunostains can be of further help such as Myogenin and Myo D1 (rhabdomyosarcoma); smooth muscle actin and desmin (leiomyosarcoma); and S100 (chondrosarcoma). However, carcinosarcomas are difficult to diagnose preoperatively. Biopsy of the tumor, especially when centrally located, often shows only one component, and peripheral tumors are difficult to reach endoscopically .
Histogenetically, Carcinosarcomas may represent malignant epithelial neoplasms undergoing divergent tissue differentiation originating from a single clone . The prognosis of these patients is unfavorable based on a small number of cases described in literature. Ishida et al reported a 9-month median survival of 5 patients . Davis et al reported a 12 month median survival time in 15 patients post resection . Huwer et al reviewed seven patients with pulmonary carcinosarcoma out of 2,400 cases of lung cancers and found that mortality was related to tumor recurrence or distant metastasis of the sarcoma component . In a clinicopathologic study, Koss et al retrospectively reviewed 66 patients with pulmonary carcinosarcoma from the archives of the Armed Forces Institute of Pathology (AFIP), and compared them to 33 cases of pleomorphic carcinoma and found that carcinosarcomas had poor prognosis with a 5-year survival rate of 21.3%. Of several clinical and pathologic parameters, only tumor size (6 cm or more) appeared to be related to reduced survival (p = 0.0195) .
Invasive Aspergillosis, is a major cause of morbidity and mortality in the severely immunocompromised. Risk factors include prolonged and severe neutropenia, hematopoietic stem cell and solid organ transplantation, advanced AIDS, and chronic granulomatous disease . It is rarely found in patients with solid tumors and in the absence of the afore mentioned major risks factors. In retrospective microbiology studies of patients with "proven" and "probable" invasive aspergillosis based on the European Organization for Research and Treatment of Cancer, and the Mycosis Study Group of the National Institute of Allergy and Infectious Diseases criteria between 1993-2003, only 1 of a total of 13 patients who met the criteria for invasive aspergillosis was found to have lung cancer [10–12]. Steroid use and lymphopenia were common risk factors among the patients with solid tumors and invasive aspergilosis . An autopsy review at M. D. Anderson Caner Center of 588 patients with hematologic malignancies and 144 patients with solid tumors done between 1993-2002 revealed that 102 (17.3%) had hematologic malignancies, while only 1 patient (0.68%) had solid tumor (p < 0.01) . The findings of this studies, as in our case, are in agreement with previous studies that invasive aspergillosis is much more common in patients with hematologic than in solid malignancies.
Nivoix Y et al retrospectively analyzed 289 patients with presentation that fulfilled the criteria for possible, probable, or proven invasive aspergillosis according to the international definitions. The predictors of increased overall mortality were in patients who received allogenic hematopoietic stem cell or solid-organ transplant, prior respiratory disease, corticosteroid therapy, renal impairment, low monocyte counts, disseminated aspergillosis, diffuse pulmonary lesions, pleural effusion, and proven or probable aspergillosis .
In our case, the invasive aspergillosis and the subsequently diagnosed carcinosarcoma occupied the same location of the left upper lobe. The typical tissue reaction in aspergillus pneumonia is known to be hemorrhagic infarction with a sparse inflammatory infiltrate , and our case revealed similar features. In addition, despite complete course of antifungal therapy, occasional foci of residual aspergillus hyphae were identified in such areas of hemorrhagic infarction.
In conclusion, the combination of invasive aspergillosis and solid malignancies is an extremely rare occurrence. To the best of our knowledge, there has not been any reported case of pulmonary carcinosarcoma and invasive aspergillosis in the literature. Furthermore, this case report is significant because the patient did not have any of the commonly described risk factors for developing invasive aspergillosis. Limited studies found in literature have shown poor prognosis in patients with either invasive aspergillosis or pulmonary carcinosarcoma. Whether the coexistence of these two entities in a patient increases mortality remains to be determined in case series, retrospective or prospective studies.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Jenkins BJ: Carcinosarcoma of the lung. J Thorac Cardiovascular Surg. 1968, 55: 657
- Travis WD, Brambilla E, Muller-Hermelink HK: Pathology and Genetics: Tumors of the lung, pleura, thymus and heart. 2004, Lyon: IARC
- Koss MN, Hochholzer L, Frommelt RA: Carcinosarcomas of the lung: A clinico pathologic study of 66 patients. Am J Surg Pathol. 1999, 23: 1514-1526. 10.1097/00000478-199912000-00009.View ArticlePubMed
- Huwer H: Pulmonary carcinosarcoma; diagnostic problems and determinants of the prognosis. Eur J Cardiothoracic surgery. 1996, 10: 403-407. 10.1016/S1010-7940(96)80105-9.View Article
- Diaconita G: Bronchopulmonary carcinosarcoma. Thorax. 1975, 30: 682-686. 10.1136/thx.30.6.682.PubMed CentralView ArticlePubMed
- Davis MP, Eagan RT, Weiland LH, Pairolero PC: Carcinosarcoma of the lung: Mayo Clinic experience and response to chemotherapy. Mayo Clinic Proc. 1984, 59: 598-603.View Article
- Holst VA, Finkelstein S, Colby TV: p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histiogenesis. Am J surg pathol. 1997, 21: 801-811. 10.1097/00000478-199707000-00008.View ArticlePubMed
- Ishida T, Tateishi M, Kaneko S, Yano T: Carcinosarcoma and spindle cell carcinoma of the lung clinicopathologic and immunohistochemical studies. J Thoracic Cardiovascular Surg. 1990, 100: 844-852.
- Segal BH, Walsh TJ: Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006, 73 (7): 707-17. 10.1164/rccm.200505-727SO.View Article
- Ohmagari N, Raad II, Hachem R, Kontoyiannis DP: Invasive Aspergillosis in Patients with Solid Tumors. Cancer. 2004, 101 (10): 2300-2. 10.1002/cncr.20647.View ArticlePubMed
- Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A: Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008, 47 (9): 1176-84. 10.1086/592255.View ArticlePubMed
- Ascioglu S, Rex JH, de Pauw B: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002, 34: 7-14. 10.1086/323335.View ArticlePubMed
- Meyer R, Young L, Armstrong D, Yu B: Aspergillosis complicating neoplastic disease. Am J Med. 1973, 54: 6-10.1016/0002-9343(73)90077-6.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.